



TAKE A STEP CLOSER TO CURATIVE SURGERY



THE SMARTT Y90 PROGRAMME

SIRT Multidisciplinary AppRoach with TheraSphere™ Therapy

A unique peer-to-peer educational programme that explores how personalised neoadjuvant TheraSphere Y90 Therapy can downstage/bridge patients to curative surgery





THE SMARTT Y90 PROGRAMME

SIRT Multidisciplinary AppRoach with TheraSphere™ Therapy

The SMARTT Y90 Programme is unique peer-to-peer educational initiative exploring the treatment of liver cancer, with a focus on controlling and downstaging HCC.

This is an ambitious long-term initiative, through which we are building a dynamic, interactive forum of transplant surgeons, hepatologists and other liver cancer specialists. The programme will explore the role of personalised TheraSphere Y90 Therapy, **proven to bridge and downstage patients with intermediate and advanced HCC to curative surgery.**

We launched SMARTT Y90 in June with our first livestream workshop, but If you missed it, it's not too late to view on demand and to participate in the next stages of the programme.

Steering Committee

The programme has been developed in co-operation with multi-disciplinary specialists who will take an active role in the delivery of the curriculum.



Prof. Deniz Balci
HPB & Transplant Surgeon, Istanbul, Turkey



Dr. Sherrie Bhoori
Hepatologist, Milan, Italy



Dr. Maria Varela
Hepatologist, Oviedo, Spain



Prof. Riad Salem
Interventional Radiologist, Chicago, IL USA



Dr. Irene Bargellini
Interventional Radiologist, Turin, Italy



Prof. Etienne Garin
Nuclear Physicist, Rennes, France



Dr. David Pinato
Medical Oncologist, London, UK



Prof. Dirk Arnold
Medical Oncologist, Hamburg, Germany



Dr. José Martínez
Interventional Radiologist, Valencia, Spain

Additional faculty members include:





THE SMARTT Y90 CURRICULUM OVERVIEW 2023/2024

Advances in Locoregional Neoadjuvant Therapy for HCC Changing the Landscape in Patient Management

Workshop 1
broadcast on
14 June 2023



1 hour

**Impact of TheraSphere™ Y90
Therapy on liver function**
Dr. Maria Varela
Hepatologist, Oviedo, Spain

**TheraSphere Y90 Therapy
for downstaging:
from right to left of BCLC**
Dr. Sherrie Bhoori
Hepatologist, Milan, Italy

**Role of downstaging
in the expanding field
of transplant oncology**
Prof. Deniz Balci
HPB & Transplant Surgeon,
Istanbul, Turkey

WATCH ON DEMAND 

Livestream Workshop 2
on
27 Sept 2023



1 hour

**Real-world case
discussion from a multidisciplinary
team (MDT) perspective**

REGISTER NOW 

**Dedicated Ask-the-Expert
Interface**
Oct-Dec 2023



**A unique opportunity for a dedicated
virtual meeting between your centre's
MDT and members of our Steering
Committee and Faculty.**

Raise specific questions and explore
how personalised TheraSphere Y90
Therapy could expand curative options
to improve your patient outcomes.

**2024
Curriculum**

**The 2024 programme will
feature livestream activity
and face-to-face local and
regional summit meetings.**

Our SMARTT Y90 Ask-the-Expert service will continue, offering you and your centre's MDT the chance for a customised virtual meeting with members of the expanding SMARTT Y90 Faculty.



Visit the website
to register for
SMARTT Y90 updates



ABOUT THERASPHERE™ Y90 THERAPY


The most powerful SIRT therapy available, the TheraSphere Y90 dose can be personalised to each patient to deliver highly targeted radiation to the tumour(s) while preserving healthy liver tissue.

Twenty years of clinical evidence supports the efficacy of TheraSphere Y90 throughout the HCC treatment pathway – including as a valuable neoadjuvant therapy that can downstage and bridge patients to curative options.¹

The EPOCH phase III RCT demonstrated a positive progression-free survival benefit when TheraSphere Y90 is used with systemic treatment in patients with metastatic liver tumours after failed first-line therapy,² while the importance of its role in the treatment of intrahepatic cholangiocarcinoma is increasingly widely recognised.³

HCC Case Example

Unlocking Access to Curative Surgery with Therasphere: Effective Disease Control and Increased FLR



Baseline

12cm HCC in segments 5 and 8 with portal vein thrombosis



10 months post TheraSphere Y90 therapy

Atrophy of the treated right lobe with hypertrophy of the left lobe (FLR), allowing right hepatectomy to be performed



Post surgery

CT at day six post right hepatectomy

Images: Courtesy of Professor Eric Vibert, MD, PhD, IKO, Hepatobiliary Surgeon, Paul Brousse University Hospital, Villejuif, France, reproduced with permission

References: **1.** Lewandowski JR, Johnson GE, Kim E, et al. Use of Yttrium-90 (Y90) Glass Microspheres (TheraSphere™) as Neoadjuvant to Transplantation/Resection in Hepatocellular Carcinoma: Analyses from the LEGACY Study. *J Clin Oncol* 2021;39(3) suppl 300. **2.** Mulcahy MF, Mahvash A, Pracht M, et al. Radioembolization with Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. *J Clin Oncol* 2021: Jco2101839. **3.** Edeline J, Touchefeu Y, Guiu B, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. *JAMA Oncol.* 2020;6(1):51–59. doi:10.1001/jamaoncol.2019.3702.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

2023 Copyright. © Boston Scientific Corporation or its affiliates. All rights reserved. PI-1648704-AA.